These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.
The Indian pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units. It is projected to reach a value of US$ 130 billion by 2030
Biopharma can benefit from the critical enablers of innovation in the private healthcare system in India
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
Healthcare leaders are heavily investing in AI or plan to do so for both critical decision support and operational efficiency, helping tackle staff shortages
The Theme of the event was 'Building One Health Together – Improving Health Equity'
The meeting provides recommendations to the G20 and its Member States and international partners on the establishment of a R&D and manufacturing network for diagnostics
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
Subscribe To Our Newsletter & Stay Updated
